Advertisement

Topics

MammaPrint® Late Recurrence (20yr) Low Risk result identifies breast cancer patients with 97% survival at 20-years with limited endocrine therapy treatment

11:13 EDT 29 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Retrospective analysis of patient samples from the prospective, randomized Stockholm Tamoxifen Trial demonstrates clinical utility of MammaPrint in identifying breast cancer patients with exceedingly low likelihoo...

Other Sources for this Article

Media Contacts:
Instinctif Partners for Agendia
Daniel Gooch / Lynne Trowbridge
Tel: +44 (0) 20 7866 7905
Email: agendia@instinctif.com

NEXT ARTICLE

More From BioPortfolio on "MammaPrint® Late Recurrence (20yr) Low Risk result identifies breast cancer patients with 97% survival at 20-years with limited endocrine therapy treatment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...